Anda di halaman 1dari 3

Scientists Seize Brass Ring:

Bring Promise of Tomorrow’s Medicines & Technologies Today

ATLANTA, Ga. (November 15, 2006) – Today’s revolutionary advances in science and technology have
raised expectations for remarkable new products coming from industries as diverse as automotive to
pharmaceutical; biotechnology to nanotechnology. But, how do we turn hope into reality, not for future
generations, but for our own? Products targeting important areas such as renewable energy, public health
(e.g., drug resistant bacteria), and counterterrorism are urgently needed. Other discoveries leading to
advances in electronics, solar energy utilization, and lightweight, high-strength materials would not only
make life more convenient, but would create hundreds of thousands of new jobs in the slumping US high-
tech sector. However, there is growing concern that many of these laboratory discoveries may never
reach the consumer. In the pharmaceutical industry, for example, there has been a slowdown, instead of
the expected acceleration, in new drugs reaching patients. The automotive industry has been hampered
by the exorbitant cost associated with the development of fuel cell technologies, and the biotechnology
and nanotechnology sectors have failed to live up to the hype to deliver more effective, more affordable
and safe products. With all of the highly publicized scientific breakthroughs, why aren’t the benefits of
these discoveries available to the consumer today?

In one company’s view, ODIN Industries a Georgia-based molecular engineering company, the problem is
not unlike the one found in the automotive industry before the development of the assembly line – The
evolution of the methods needed to bring these new discoveries from the laboratory to the market quickly
and at an affordable price have not kept pace with the rate of discovery. In many cases, the most
beneficial products are stuck in the development pipeline, and companies concentrate their efforts on
“low hanging fruit”: ordinary products with high market return.
Tragically, many significant discoveries are not commercialized, and Table 1.
Some Macrocycle-Based Technologies
more importantly, life-altering research is greatly impeded.
Antimicrobials for textiles
New Doors Opened Biological and chemical detection
Boron-Neutron Capture Therapy (BNCT)
Inspired by Ford’s assembly line concept, ODIN attacked the current Disease detection & treatment
barriers to the commercialization of many new technologies from a Drug delivery
chemistry viewpoint - Two major goals were addressed. The first Dyes
was to identify the components that are preventing vital technologies Flavors and Fragrances
Food preservatives
from reaching the market, and the second was to design a 21st century Fuel cells
process that would make them simple and cost-effective to produce. Injection molded plastics
Hydrogen fuel production
During the course of its research, ODIN was stunned by the number Light-Emitting Diodes (LEDs)
Light rods for solar energy conversion
of cutting-edge technologies that teeter on the edge of success Lubricants
because of the difficulty in obtaining a single family of components Magnetic materials
called “macrocycles,” the complex, compelling rings of chemistry. Magnetic Resonance Imaging (MRI)
These doughnut-shaped molecules, mainly composed of carbon, Molecular wires
Multi-bit storage memory
nitrogen and oxygen have a central hole or “ring” that give them Nerve regeneration
nearly magical properties. Macrocycles are abundant in nature, and Nonlinear optic materials (NLOs)
their potential uses are limitless, making them the subject of intense Optical gates
research (Table 1.). And for more than 50 years macrocycles have Paint
Photodynamic Therapy (PDT)
been a wellspring of drug leads, serving as the inspiration for nearly Positron Emission Tomography (PET)
every new drug introduced by the pharmaceutical industry. Industry Purification (e.g. water, blood)
icons such as Insulin, FK-506, Taxol, and Vancomycin are all Separation science
Athens, GA 30605 • Tel: (706) 540-7325 •
Accordingly, macrocycles constitute a major class of pharmaceutical agents currently under pre-clinical
and clinical investigation for the treatment of virtually every disease (Table 2.).

Notwithstanding their long history as lead compounds, very few intact

Table 2.
Macrocycles in Medicine The macrocycles make it to market. This difficulty is NOT due to a small
macrocyclic structure is a number of promising leads. Quite the contrary, over the past decade, the
particularly desirable feature for number of macrocycles has increased in an explosive manner. In fact,
the pharmaceutical industry. The the macrocyclic structure is arguably the most diverse structure found in
ring-like structure stabilizes the nature. Paradoxically, the ring-like nature of this class of molecules has
drug from destruction by the
human body and increases its
made it notoriously difficult and expensive to obtain them in sufficient
effectiveness by locking it into a quantities – making them the “poster-child” for the challenges
biologically active form. associated with bringing scientific discoveries from the laboratory to the
Macrocycle-based drugs are marketplace. Some macrocycles cost as much as $17 million dollars per
currently under investigation for kilogram (approximately the size of a 2 lb bag of sugar); while others
the treatment of:
would require the total destruction of whole species of plants and
All Cancer animals in order to obtain enough material to conduct research with
Cardiomyopathy them. Thus, regardless of the great promise shown by macrocycles in
Coronary artery disease the laboratory, the barriers of cost and scarcity have prevented the
Dementia advancement and development of macrocycle-based technologies in
Diabetes virtually every discipline.
Drug resistant bacteria
Fragile X syndrome Motivated by the potential of these valuable and highly sought-after
Lou Gehrig's disease - ALS molecules, ODIN developed a revolutionary new method to assemble
Lupus them. This proprietary process, radical as it is simple, enables the
Macular degeneration preparation of all important macrocycles using compact synthetic
Mad Cow disease -TSE
Multiple Sclerosis (MS)
schemes, so that no useful compound is inaccessible to practical
Hepatitis C synthesis. The key innovation is the simultaneous control of undesired
HIV products and removal of the desired macrocycle. Under the conditions
Obesity of the reaction undesired products form, break apart, and reform, until
Parkinson’s Disease the macrocycle emerges and is removed. Then the other products
Psoriasis spontaneously generate more macrocycle and are also removed – This
Rheumatoid arthritis
Stroke process continues until virtually all of the products are converted to the
macrocycle. The reversible nature of the reaction provides the error
checking and proof-reading required for the efficient formation of a single product. By incorporating
“green” practices into their procedure, the ODIN process also dramatically reduces the quantity of
harmful by-products.

But the most important aspect of ODIN’s process is that it standardizes the method of macrocycle
production, thus putting all scientists in all disciplines and fields on the same page. Rather than using “ad
hoc” or specialized procedures to create these complex molecules, ODIN’s simplified process drastically
reduces the cost of drugs and technologies that might not otherwise make it from the laboratory to the

However, the implications of the ODIN process go far beyond the mere creation, development, and
manufacture of macrocycles. It is a universal process, not an end product, which can be operational in
research laboratories throughout the world within months. Using existing facilities and current scientific
teams, ODIN’s discovery, like the breakthrough brought about by the assembly line, will open up entirely
new vistas of exploration. With a technology geared to meet the needs of the 21st century and beyond, the
potential for new products, new markets, and job growth is enormous. ODIN’s core technology gives
entire industries new tools to break through old barriers, allowing them the freedom to focus on solving
the next great challenges of our century.

Athens, GA 30605 • Tel: (706) 540-7325 •

About ODIN

ODIN Industries is a leading molecular engineering company specialized in macrocycle R&D,

technology assessment, and pharmaceutical pipeline development. The company’s proprietary
technology gives companies the ability to exploit vast, undeveloped chemical space, re-establish strong
patent protection, and deliver big profit margins on molecules that have had little or no commercial
viability. Through internal and external programs, licensing, and partnerships, ODIN is working to drive
the discovery and development of new diagnostics, therapeutics and other macrocycle-based

Media Contact Information

Matt O’Conner, McRae Communications, at (770) 460-7277 or

Industry Support & Investor Information

John R. Cool, Communications and Marketing, at (612) 332-7676 or

Athens, GA 30605 • Tel: (706) 540-7325 •